Phase I/II Clinical Trials for Theradaptive OsteoAdapt SP

Theradaptive gained approval from FDA for their Investigational Device Exemption submission to begin enrolling patients into OASIS, their global Phase I/II Feasibility study in spine fusion.

Theradaptive’s spinal fusion product, OsteoAdapt SP, aims to provide safer and more effective treatments for transforaminal lumbar interbody fusion. It is...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us